Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBT Margin (2016 - 2026)

Bio-Techne has reported EBT Margin over the past 17 years, most recently at 17.16% for Q4 2025.

  • For Q4 2025, EBT Margin rose 273.0% year-over-year to 17.16%; the TTM value through Dec 2025 reached 2.25%, down 1237.0%, while the annual FY2025 figure was 0.96%, 1413.0% down from the prior year.
  • EBT Margin for Q4 2025 was 17.16% at Bio-Techne, up from 16.75% in the prior quarter.
  • Over five years, EBT Margin peaked at 5185.8% in Q3 2022 and troughed at 61.09% in Q2 2022.
  • A 5-year average of 269.44% and a median of 17.53% in 2025 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: soared 515965bps in 2022 and later plummeted -516790bps in 2023.
  • Year by year, EBT Margin stood at 32.0% in 2021, then decreased by -24bps to 24.46% in 2022, then tumbled by -50bps to 12.25% in 2023, then rose by 18bps to 14.43% in 2024, then grew by 19bps to 17.16% in 2025.
  • Business Quant data shows EBT Margin for TECH at 17.16% in Q4 2025, 16.75% in Q3 2025, and 34.6% in Q2 2025.